Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Acute Rheumatic Fever
NCT05682196Phase 2Suspended
- Sponsor
- African Academy of Methodology and Statistics
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in acute rheumatic fever (ARF), sponsored by African Academy of Methodology and Statistics. Started Jan 2023; status: suspended.
02
Drugs
rituximab
03
Conditions
acute rheumatic fever (ARF)
Beyond the preview
Go deeper on NCT05682196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682196.